Skip to content

Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease

Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06036992
Acronym
COMPLIK
Enrollment
600
Registered
2023-09-14
Start date
2023-10-01
Completion date
2027-08-01
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Kidney Diseases

Brief summary

Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related complications are common: intracystic haemorrhage, renal or hepatic cyst infections, cyst-related mechanical complications and lithiasis. To date, there is no reliable epidemiological data on the frequency and clinical impact of these complications. Diagnosis of these complications is often complicated, and their management has not been codified. The latest international recommendations (KDIGO) provide only low-level recommendations. For the most complex cases (recurrent cystic infections, resistant pain, mechanical complications and malnutrition, need for pre-transplant nephrectomy, etc.), practitioners are often at a loss and management varies greatly from one centre to another.

Detailed description

Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related complications are common: intracystic haemorrhage, renal or hepatic cyst infections, cyst-related mechanical complications and lithiasis. To date, there is no reliable epidemiological data on the frequency and clinical impact of these complications. Diagnosis of these complications is often complicated, and their management has not been codified. The latest international recommendations (KDIGO) provide only low-level recommendations. For the most complex cases (recurrent cystic infections, resistant pain, mechanical complications and malnutrition, need for pre-transplant nephrectomy, etc.), practitioners are often at a loss and management varies greatly from one centre to another.

Interventions

None listed

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with autosomal dominant polycystic kidney disease (APKD) participating in the Genkyst study * Patient with at least one cystic complication. The cystic complications retained are the following: * Acute or chronic cyst-related pain requiring analgesic treatments * Cyst infection * Intracystic haemorrhage * Urinary lithiasis * Functional complaints related to the cystic mass: digestive disorders with eating disorders, undernutrition, diaphragmatic compression phenomena, portal hypertension, umbilical or linea alba hernias, ventrations * Need for a cystic reduction procedure: puncture, marsupialization, open surgery (including preparation for grafting)

Exclusion criteria

* Patients who have expressed their opposition to taking part in the study * Patient under legal protection (guardianship, curatorship, etc.)

Design outcomes

Primary

MeasureTime frameDescription
To improve knowledge of the epidemiology of cystic complications within the Genkyst network12 monthsnumber of cases of cystic complications per year per complication

Secondary

MeasureTime frameDescription
Creation of a specific multidisciplinary consultation meeting12 monthsMeetings and exchanges between different health professionals: interventional radiologists, surgeons, infectiologists, hepatologists, pain specialists and nephrologists to discuss the best possible management for patients with complex cystic complications.
Creation of an image bank12 monthsconsulting images to recalculate and improve diagnostic scores
Creation of a group of control patients12 monthsthe change from baseline in quality of life scores at 1 year.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026